Market capitalization | HKD91.80b |
Enterprise Value | HKD40.53b |
P/E (TTM) P/E ratio | 31.90 |
EV/FCF (TTM) EV/FCF | 5.88 |
EV/Sales (TTM) EV/Sales | 0.68 |
P/S ratio (TTM) P/S ratio | 1.55 |
P/B ratio (TTM) P/B ratio | 1.63 |
Revenue growth (TTM) Revenue growth | -1.91% |
Revenue (TTM) Revenue | HKD59.26b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a JD Health International forecast:
15 Analysts have issued a JD Health International forecast:
Jun '24 |
+/-
%
|
||
Revenue | 59,256 59,256 |
2%
2%
|
|
Gross Profit | 13,377 13,377 |
2%
2%
|
|
EBITDA | 1,094 1,094 |
10%
10%
|
EBIT (Operating Income) EBIT | 853 853 |
10%
10%
|
Net Profit | 2,835 2,835 |
46%
46%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
JD Health International, Inc. operates as an online healthcare platform and retail pharmacy company. Its technology-driven platform is cantered on the supply chain of pharmaceutical and healthcare products and healthcare services, encompassing a user’s full life span for all healthcare needs. The firm's retail pharmacy business operates through three models: direct sales, online marketplace and Omni channel initiative. It offers comprehensive online healthcare services, such as online consultation and prescription renewal, chronic disease management, family doctor and consumer healthcare. Its platform allows doctors to practice multisite, acquire and manage targeted patients, conduct healthcare research, exchange academic and clinical knowledge and improve diagnostic and treatment skills. The company was founded on November 30, 2018 and is headquartered in Beijing, China.
Head office | Cayman Islands |
CEO | En Jin |
Employees | 3,118 |
Founded | 2018 |
Website | www.health.jd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.